However, these processes are often inhibited in tumor-infiltrating cDCs through high expression of the inhibitory receptor T-cell immunoglobulin and mucin domain 3 (TIM3), which interacts with alarmin HMGB1, inhibiting anti-tumor responses and reducing the efficacy of cancer treatments (304, 305). This evidence concerns the gene HMGB1 and neoplasm.